Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Curbing C. difficile's toxin production

Curbing C. difficile's toxin production

September 06, 2007

As if being admitted to the hospital weren't bad enough, patients, once admitted, are at higher risk of becoming infected with a "superbug" bacterium, Clostridium difficile (C. difficile). The toxins produced by C. difficile kill human intestinal cells by causing them to burst open, allowing the bacteria to use them as fuel. This results in severe diarrhea and, in rare cases, death. Abraham "Linc" Sonenshein, PhD, and colleagues from the Department of Molecular Biology and Microbiology at the Tufts University School of Medicine (TUSM) and the Sackler School of Graduate Biomedical Sciences at Tufts, have discovered how a protein called CodY regulates the genes that control production of the dangerous toxins. Understanding the relationship between CodY and C. difficile is an important step toward the development of a drug that may prevent hospital patients from falling ill.

"The C. difficile bacteria only produce toxins when they are in need of food," explains Sonenshein, professor of microbiology at TUSM and corresponding author on the paper to be published in Molecular Microbiology. "We found that the CodY protein, in essence, monitors the hunger level of C. difficile, preventing toxin production when the bacteria have enough to eat." Sonenshein, along with first author Sean Dineen, PhD, and other Tufts colleagues developed a series of experiments to investigate the importance of CodY and how this protein communicates to bacteria that it is time to search for new sources of food.




The researchers first developed a mutant strain of C. difficile bacteria that does not make the protein CodY, and compared the amount of toxin produced by the mutant strain of bacteria to the amount of toxin produced by normal bacteria. The mutant strain produced much higher levels of toxin. The presence of CodY seems to tell the bacterial cells that they are well-fed and there is no reason to make toxin that kills intestinal cells for fuel. Lack of CodY activity, however, indicates to the bacteria that they are lacking key nutrients and that it is time to make the toxins they need to get food from the host cells.

To determine how CodY tells the bacteria not to make toxins, Sonenshein and colleagues removed DNA from the bacteria, and observed the interaction of the DNA and the CodY protein in vitro. They found that CodY targeted the region of the bacterial chromosome that includes the toxin genes. "When CodY senses that the cell has enough nutrients, it binds to this gene region, and prevents the bacterium from making toxin," says Sonenshein. "Conversely, when food is scarce, the CodY protein does not bind to these genes, allowing C. difficile to make the toxins needed to attack intestinal cells."

Knowing what turns on, and more importantly, what turns off the toxin-producing genes in C. difficile opens the door for treatment and prevention options. "It is possible that, based on our findings, a new drug could be developed that would trick CodY into thinking there is enough fuel for the bacteria, causing CodY to remain bound to the toxin gene region and thus suppressing toxin production."

Tufts University, Health Sciences



Related Clostridium Difficile Current Events and Clostridium Difficile News Articles Clostridium Difficile Current Events and Clostridium Difficile News RSS Clostridium Difficile Current Events and Clostridium Difficile News RSS
Commentary warns of unexpected consequences of proton pump inhibitor use in reflux disease
Despite being highly effective and beneficial for many patients, unexpected consequences are emerging in patients who are prescribed proton pump inhibitors (PPIs) for reflux diseases.

Deadly stomach infection rising in community settings, Mayo Clinic study finds
Mayo Clinic researchers have found that a sometimes deadly stomach bug, Clostridium difficile is on the rise in outpatient settings.

Eating right, not supplements, is best at keeping your good bacteria healthy, dietitian says
Healthy eating, not supplements, is the best way to keep the good bacteria in your gut healthy, says a dietitian and researcher.

Structure of antibiotic ramoplanin reveals promising mechanism
With the "last resort" antibiotic Vancomycin now plagued by the first signs of bacterial resistance, a scientific collaboration centered at Duke University has identified how a candidate successor antibiotic known as Ramoplanin A2 can kill pathogenic bacteria by interrupting how they form their cell membranes.

Antibiotics take toll on beneficial microbes in gut
It's common knowledge that a protective navy of bacteria normally floats in our intestinal tracts. Antibiotics at least temporarily disturb the normal balance.

Newly discovered reactions from an old drug may lead to new antibiotics
A mineral found at health food stores could be the key to developing a new line of antibiotics for bacteria that commonly cause diarrhea, tooth decay and, in some severe cases, death.

Doctors identify patients at high risk of C. difficile
Doctors have developed and validated a clinical prediction rule for recurrent Clostridium difficile (C. difficile) infection that was simple, reliable and accurate, and can be used to identify high-risk patients most likely to benefit from measures to prevent recurrence. Their findings appear in a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

Hospital infection control strategies for antibiotic-resistant organisms
Hand-washing, a clean environment, appropriate infection barriers and early identification of patients at high risk of colonization with a transmissible microorganism remain the essential measures to prevent and control infection.

What makes C-Diff superbug deadly?
A major breakthrough about the potentially deadly superbug Clostridium difficile (C-diff) could lead to new ways to combat the bacterium, according to a study to be published March 1 in the journal Nature.

Monash scientists debug superbug
An international team of scientists, led by Monash University researchers, has uncovered the workings of a superbug that kills elderly hospital patients worldwide - a discovery that has the potential to save lives and health care systems billions of dollars each year.
More Clostridium Difficile Current Events and Clostridium Difficile News Articles
Bacteria for Breakfast: Probiotics for Good Health

Bacteria for Breakfast: Probiotics for Good Health
by Kelly Dowhower Karpa, PhD, RPh (Author)

Although in Western society the beneficial aspects of bacteria have been increasingly minimized, we actually need bacteria in our digestive tracts for good health. This resource explains, to laymen and physicians, how probiotics support immune function, prevent urogenital infections, and maintain good gastrintestinal health.

  Clostridium Difficile Test (25 per Pack)
by Marion Scientific

A 20 minute latex agglutination test for C. difficile associated diarrhea, 5 minutes hands on time, requires no instrument, excellent screening tes for stool specimenst, sensitivity found to be from 92 to 95%, negative predictive value 97 to 98%, controls included, performs 25 patient tests.

Giantmicrobes C. Diff Clostridium Difficile [Toy]

Giantmicrobes C. Diff Clostridium Difficile [Toy]
by Giantmicrobes

Giant Microbes are soft, cute, durable, well made, educational, and just a lot of fun too! Each 5-to-7 inch doll is accompanied by an image of the real microbe it represents, as well as information about the microbe. Give it up for C. Diff, hospital's notorious gangsta.

Meridian Immunocard Toxins A & B Kit, 50 Tests

Meridian Immunocard Toxins A & B Kit, 50 Tests
by Meridian Bioscience

Features of the Meridian Immunocard Toxins A & B Kit: Membrane EIA single test for the qualitative detection of Clostridium difficile Toxins A and B in Stool Specimens. High sensitivity: both Toxin A and Toxin B are detected. Rapid detection: results in 15 minutes. No sample pre-treatment required. No reagent dilution required. Easy and single test procedure. Internal control of the procedure on each card. Kit Components: Test cards, specimen diluent, enzyme conjugate, positive control, wash reagent, substrate reagent, transfer pipettes. The product referenced on this detail page is sold be 50/bx.

Clostridium difficile (Current Topics in Microbiology and Immunology)

Clostridium difficile (Current Topics in Microbiology and Immunology)
by K. Aktories (Editor), T.D. Wilkins (Editor)

Clostridium difficile has been recognized as the cause of a broad spectrum of enteric disease ranging from mild antibiotic-associated diarrhea to pseudomembranous colitis. This volume gives new insights into the microbiology, diagnostics and epidemiology of Clostridium difficile and describes recent strategies in treatment of diseases caused by this agent. Main parts of the volume are devoted to Clostridium difficile toxins A and B which are the major virulence factors. The molecular biology, biochemistry, pharmacology and cell biology of these toxins which are the prototypes of a new family of large clostridial cytotoxins is described in great detail. Clostridium difficile toxins act as glucosyltransferases to inactivate small GTP-binding proteins of the Rho family which are involved in...

  Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003 (1).(RESEARCH): An article from: Emerging Infectious Diseases
by L. Clifford McDonald (Author), Maria Owings (Author), Daniel B. Jernigan (Author)

This digital document is an article from Emerging Infectious Diseases, published by Thomson Gale on March 1, 2006. The length of the article is 5384 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003 (1).(RESEARCH)
Author: L. Clifford McDonald
Publication: Emerging Infectious Diseases (Magazine/Journal)
Date: March 1, 2006
Publisher: Thomson Gale
Volume: 12 Issue: 3 Page: 409(7)

Distributed by Thomson...

  Guide to the Elimination of Clostridium Difficile
by Ruth Carrico (Author)



  Clostridium Difficile: Its Role in Intestinal Disease
by Author Unknown (Author)

Despite the tremendous progress made during the last few years in understanding the pathogenesis, epidemiology, diagnosis, and treatment of Clostridium difficile-associated intestinal disease, many extremely important and fundamental questions remain to be answered. The objectives of this book are to summarize the available information regarding Clostridium difficile and its role in intestinal disease and to serve as a basis for future investigations in this challenging area.
Clostridium difficile: its role in Intestinal Disease. An excellent volume that should appeal not only to the devotee of C difficile but to all gastroenterologists and microbiologists, this will not languish on my library shelves like so many other books I have reviewed. It will be regularly thumbed. --R.H....

  Fecal transfer cures relapsing C. diff infection.(GASTROENTEROLOGY)(clostridium difficile): An article from: Internal Medicine News
by Miriam E. Tucker (Author)

This digital document is an article from Internal Medicine News, published by International Medical News Group on January 1, 2009. The length of the article is 985 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.

Citation Details
Title: Fecal transfer cures relapsing C. diff infection.(GASTROENTEROLOGY)(clostridium difficile)
Author: Miriam E. Tucker
Publication: Internal Medicine News (Magazine/Journal)
Date: January 1, 2009
Publisher: International Medical News Group
Volume: 42 Issue: 1 Page: 24(1)

Distributed by Gale, a part of Cengage...

  Clostridium difficile (Methods in Molecular Biology)
by Peter Mullany (Editor), Adam P. Roberts (Editor)

This book reviews the state of the art of methods available for the molecular analysis and investigation of virulence of the important human pathogen Clostridium difficile.



© 2009 BrightSurf.com